Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
IBC 2024
The 2nd Intercepting Blood Cancers Workshop (IBC)
14–16 March 2024 | Lisbon, Portugal
Explore expert-led presentations from the 2nd Intercepting Blood Cancers Workshop (IBC) on topics including:
- Lymphoma, chronic lymphocytic leukemia (CLL), monoclonal B-cell lymphocytosis (MBL) and lymphoma
- Multiple myeloma, smoldering myeloma (SMM) and monoclonal gammopathy of unknown significance (MGUS)
- Myelodysplastic syndromes (MDS), clonal hematopoiesis of indeterminate potential (CHIP), acute myeloid leukemia (AML) and clonal cytopenia of undetermined significance (CCUS)
View our roundtable discussions here: Myeloma/SMM/MGUS | CLL/MBL/Lymphoma | MDS/CHIP/AML/CCUS
Plenary Session 1: Early detection and screening – should we screen everyone or people at risk, germline risks?
Keynote: the best cancer is the cancer that never happens
Philip Castle NCI Prevention & Early Detection, Bethesda, MD, United States
Genomic evolution in MM
Nikhil Munshi Dana-Farber Cancer Institute, Boston, MA, United States
Germline predisposition in CLL
Susan Slager Mayo Clinic, Rochester, MN, United States
Genomic evolution from MGUS to MM
Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States
Plenary Session 2: Risk stratification and biomarkers –
tumor, immune, non-immune marker, germline and clinical biomarkers (part 1)
Keynote: Global surveillance of carcinogen exposures using somatic mutations
Michael Stratton Wellcome Sanger Institute, Cambridge, United Kingdom
Origin of the precursor state in MM
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
Immune biomarkers for predicting risk of premalignant to malignant indolent lymphoma
Stephen Ansell Mayo Clinic, Rochester, MN, United States
NGS to differentiate MN from other cytopenic conditions
Catherine Cargo Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Immune regulation in disease progression from MGUS to MM
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
Plenary Session 3: Risk stratification and biomarkers –
tumor, immune, non-immune marker, germline and clinical biomarkers (part 2)
Minimally invasive tumor and immune-based stratification
Bruno Paiva University of Navarra, Pamplona, Spain
Genetic ancestry and CH
George Vassiliou University of Cambridge, Cambridge, United Kingdom
Mechanisms of disease progression from MBL to CLL
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
Plenary session 4: Interception – endpoints of trials, which patient population, diverse populations
Keynote: FDA – endpoints and trial designs in precursor conditions
Nicole Gormley Food and Drug Administration (FDA), Bethesda, MD, United States
The future of clinical trials and endpoints in early interception of myeloma
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Early intervention in SMM
Elizabeth O'Donnell Massachusetts General Hospital, Boston, MA, United States
Novel immune therapeutics in SMM
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
Tools to predict early progression/clonal evolution to identify patients with B-cell malignancies for early intervention
Anna Schuh University of Oxford, Oxford, United Kingdom
Early intervention approaches in CLL
Matthew Davids Dana-Farber Cancer Institute, Boston, MA, United States
PIMMS study (decentralized trial of ivosidenib in CCUS)
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States
The utility of longitudinal clinical follow up in CHIP clinics: A 2024 update
Eric Padron Moffitt Cancer Center, Tampa, FL, United States
Keynote session 4
Vision of early interception, and barriers & opportunities for a cure
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
New approaches to tackling diversity challenges
Lachelle Weeks Dana-Farber Cancer Institute, Boston, MA, United States
Early detection for high-risk cancer patients in Africa
Anna Schuh University of Oxford, Oxford, United Kingdom
Multiple Myeloma/SMM/MGUS track
The iStopMM study – screening for MGUS
Sigurdur Kristinsson University of Iceland, Rekjavik, Iceland
The PROMISE study and other screening efforts so far
Elizabeth O'Donnell Massachusetts General Hospital, Boston, MA, United States
Risk stratifying MGUS
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
The evolution of risk stratification in smoldering myeloma
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Circulating tumor cells and other novel biomarkers to be added to the current models
Romanos Sklavenitis-Pistofidis Broad Institute, Boston, MA, United States
Biomarkers and imaging in precursor myeloma
Elena Zamagni University of Bologna, Bologna, Italy
Can epigenetics help us to understand the transition from MGUS to MM
Felipe Prósper University of Navarra, Navarra, Spain
Non-drug approaches to intervention
Urvi Shah Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Characterising risk and biology of SMM for early detection and intervention
Kwee Yong University College London Hospitals NHS Foundation Trust, London, United Kingdom
Prevention studies in MGUS and SMM
Catherine Marinac Dana-Farber Cancer Institute, Boston, MA, United States
What is the ideal time to intervene in smoldering myeloma?
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Therapy-related CH and multiple myeloma therapies
Adam Sperling Dana-Farber Cancer Institute, Boston, MA, United States
MDS/CHIP/AML/CCUS track
The evolution of clonal hematopoiesis to AML
Caroline Watson University of Cambridge, Cambridge, United Kingdom
CH in stem cell transplant recipients
Coleman Lindsley Dana-Farber Cancer Institute, Boston, MA, United States
Clonal selection of hematopoietic stem cells after transplantation
Michael Spencer Chapman Wellcome Sanger Institute, Cambridge, United Kingdom
The impact of chemotherapy on normal hematopoiesis
Emily Mitchell University of Cambridge, Cambridge, United Kingdom
CHIP mutations in pre-leukemia vs. frank AML with focus on DNMT3A
Ravi Majeti Stanford University School of Medicine, Stanford, CA, United States
Clonal Hematopoiesis in telomere and inflammatory disorders (CH in VEXAS syndrome)
Mrinal Patnaik Mayo Clinic, Rochester, MN, United States
Prediction models in CH
Muxin Gu Wellcome Sanger Institute, Cambridge, United Kingdom
The role of TCL1A in promoting clonal hematopoietic disorders
Siddhartha Jaiswal Stanford Medicine, Stanford, CA, United States
Deconvoluting clonal and cellular architecture in IDH-mutant myeloid neoplasms
Iannis Aifantis University of New York, New York City, NY, United States
MN risk in sickle cell disease and other hereditary hemolytic anemias
Lachelle Weeks Dana-Farber Cancer Institute, Boston, MA, United States
Decitabine/cedazuridine in high-risk CCUS
Maximilian Stahl Dana-Farber Cancer Institute, Boston, MA, United States
Therapeutic vulnerabilities in CH
Siddhartha Kar University of Cambridge, Cambridge, United Kingdom
Trials in CH – challenges and opportunities
Uma Borate Ohio State University, Columbus, OH, United States
Racial differences in outcomes from CH in multiple myeloma patients
Lachelle Weeks Dana-Farber Cancer Institute, Boston, MA, United States
CLL/MBL/Lymphoma track
Identification of specific genetic drivers of CLL long before diagnosis
Anton Langerak Erasmus University Medical Center, Rotterdam, Netherlands
Charting the breeding ground of CLL
Hendrik Veelken Leiden University, Leiden, Netherlands
Tracing founder mutations/translocations – Should we be screening for lymphomas?
Sandrine Roulland Centre d'Immunologie Marseille-Luminy (CIML), Marseille, France
Modelling early FL biology in murine models
Dinis Calado The Francis Crick Institute, London, United Kingdom
Bellinzona – ctDNA as a biomarker for predicting progression/screening in lymphoma
Davide Rossi Oncology Institute of Southern Switzerland IOSI, Bellinzona, Switzerland
FL to transformed FL – can we predict?
Jessica Okosun Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Other indolent entities (MZL) to DLBCL – what can we learn?
Silvia Beà Hospital Clínic Barcelona, Barcelona, Spain
Indolent to aggressive – progression of CLL to Richter transformation
Erin Parry Dana-Farber Cancer Institute, Boston, MA, United States
Genomic and transcriptomic characterization of MBL/CLL at the single-cell level
Giovanni Tonon San Raffaele Scientific Institute, Milan, Italy
MBL
Andrew Rawstron Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Early intervention in high-risk asymptomatic CLL with acalabrutinib
Sameer Parikh Mayo Clinic, Rochester, MN, United States
PreVent-ACaLL trial and an overview of using machine-learning algorithms to assess risk of infection in CLL
Carsten Niemann Copenhagen University Hospital, Copenhagen, Denmark
IBC 2024 was supported by:
